Organon & Co.

NYSE:OGN

Pharmaceutical Preparations·JERSEY CITY, NJ

The Organon is the standard collection of Aristotle's six works on logical analysis and dialectic.

CEO

Morrissey Joseph T. Jr.

CFO

Walsh Matthew M

Summary Financials

Revenue

$6.3B

+1.4% YoY

FY 2025

Adj. EBITDA

—

Net Income

$1.0B

16.3% margin

FY 2025

EPS (Diluted)

$3.99

FY 2025

Stock Price

$6.36

-5.3%

2026-03-09

52W Range

$6.18 – $16.08

P/E Ratio

1.6x

Market Cap

$1.7B

Cash

$675.0M

FY 2025

Total Debt

$8.9B

FY 2025

Net Debt

$8.2B

FY 2025

Enterprise Value

$9.9B

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

$6.3B

+1.4% YoY

FY 2025

Adj. EBITDA

—

Net Income

$1.0B

16.3% margin

FY 2025

EPS (Diluted)

$3.99

FY 2025

Stock Price

$6.36

-5.3%

2026-03-09

52W Range

$6.18 – $16.08

P/E Ratio

1.6x

Market Cap

$1.7B

Cash

$675.0M

FY 2025

Total Debt

$8.9B

FY 2025

Net Debt

$8.2B

FY 2025

Enterprise Value

$9.9B

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

The Organon is the standard collection of Aristotle's six works on logical analysis and dialectic.

CEO

Morrissey Joseph T. Jr.

CFO

Walsh Matthew M